NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Prelude Therapeutics Incorporated (PRLD) Stock Analysis

Prelude Therapeutics Incorporated (PRLD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PRLD

$3.65

+$0.12 (+3.40%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PRLD with… →

PRLD Key Statistics

As of Oct 21, 2026
Trading
Open
$3.56
Previous Close
$3.53
Day's Range
3.47–3.78
52-Week Range
1.17–6.83
Volume
608.33K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.96
Valuation
Market Cap
$291.28M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
12.99
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.73
Financials (FY)
Revenue (FY)
$12.14M+73.43%
Net Income (FY)
−$99.50M
Profit marginThe share of revenue left as profit after all costs and taxes.
−269.75%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
65.08M
1-Year Return
+122.56%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
511.73K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PRLD closed at $3.65, +122.56% over 1 year.

Prelude Therapeutics Incorporated (PRLD) has a market capitalization of $291.28M.

In fiscal 2025, PRLD reported revenue of $12.14M.

PRLD Stock Return by Calendar Year

Prelude Therapeutics Incorporated (PRLD) return since Sep 2020: what $10,000 became

1 year
$10,000 $22,256
+122.56%
5 years
$10,000 $1,928
−80.72%
Since Sep 2020
$10,000 $1,393
−86.07%

If you had invested $10,000 in Prelude Therapeutics Incorporated (PRLD) at the close on September 25, 2020, the earliest close on record here, it would have been worth $1,393 at the close on October 21, 2026: −86.07% in total, −27.73% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+25.86%
2025+127.45%
2024−70.14%
2023−29.30%
2022−51.49%
2021−82.60%
2020 (partial year)+173.09%

As of October 21, 2026.

PRLD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$12.14M−$99.50M−819.6%
2024$7.00M−$127.17M−1,816.8%
2023$0.00−$121.83M—
2022$0.00−$115.44M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$12.14M—−$104.57M−$99.50M−819.6%
2024$7.00M—−$139.71M−$127.17M−1,816.8%
2023$0.00—−$132.28M−$121.83M—
2022$0.00—−$123.54M−$115.44M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PRLD Valuation vs Biotechnology Median

Median of 608 stocks
MetricPRLDBiotechnology medianvs median
P/S ratio12.9913.302% below
Profit margin−269.75%−38.31%231.4 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Prelude Therapeutics Incorporated (PRLD) is capitalised at $291.28M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 79.

PRLD last closed at $3.65 on October 21, 2026. That is +$0.12 (+3.40%) against the previous close. Over the past 52 weeks the price has ranged from $1.17 to $6.83. The latest close sits 211.17% above that 52-week low.

Financial Health

In fiscal 2025, Prelude Therapeutics Incorporated reported revenue of $12.14M. Against the prior fiscal year total of $7.00M, that is a change of +73.43%. The same year closed with a net loss of $99.50M. Profit margin runs at −269.75%. That is 231.4 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −0.73.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $12.14M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 12.99. On price-to-sales that is 2.32% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +122.56%. Across 5 years the annualized return works out at −28.05%. The reported beta is 0.96. Annualized volatility over the trailing 6 years is 119.95%.

Growth & Income

The record shows no dividend for PRLD.

The strongest complete calendar year on file is 2025 at +127.45%; the weakest is 2021 at −82.60%. Of the 5 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is +25.86% year to date.

Peer Comparison

Prelude Therapeutics Incorporated (PRLD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Prelude Therapeutics Incorporated PRLD $291.28M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Prelude Therapeutics Incorporated has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Visit website →